Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5QEUC)

• Drug Name: 2,6-dihydroxy-1,7-dimethoxyxanthone Drug Info
• Synonyms: calophymembranol A; 2,6-dihydroxy-1,7-dimethoxyxanthone; CHEMBL463769; AC1NRZXJ; BDBM50269644; 2,6-dihydroxy-1,7-dimethoxyxanthen-9-one

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5326145
  TTD Drug ID: DM5QEUC

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin G/H synthase 2 (COX-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[2]
Naproxen	DMZ5RGV	Bursitis		Approved	[3]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[4]
Indomethacin	DMSC4A7	Bursitis		Approved	[5]
Celecoxib	DM6LOQU	Dysmenorrhea	GA34.3	Approved	[6]
Nabumetone	DMAT2XH	Osteoarthritis	FA00-FA05	Approved	[7]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[8]
Flurbiprofen	DMGN4BY	Osteoarthritis	FA00-FA05	Approved	[9]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[10]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[1]

References

• [1] Selective cyclooxygenase-2 inhibitors from Calophyllum membranaceum. J Nat Prod. 2005 Oct;68(10):1514-8.
• [2] Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
• [3] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [4] Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Pfizer. Product Development Pipeline. March 31 2009.
• [7] Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
• [8] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [9] Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
• [10] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.